About
Small molecule therapeutics targeting essential mediators of inflammation
Areas of Focus
Categories
Small Molecule PharmaceuticalMountain West
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
312
By Phase
PHASE2: 3PHASE1: 2
By Status
COMPLETED: 3NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07172867Lead Sponsor
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
PHASE2Not yet recruiting
50 participants
Started: Sep 30, 2025 · Completed: Jun 30, 2026
NCT06537817Lead Sponsor
Study to Evaluate HT-4253 in Healthy Subjects
PHASE1Completed
80 participants
Started: Sep 17, 2024 · Completed: May 12, 2025
NCT06241742Lead Sponsor
Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
PHASE2Completed
81 participants
Started: Feb 12, 2024 · Completed: Apr 30, 2024
NCT07052006Lead Sponsor
HT-6184 in Subjects With MDS
PHASE2Active, not recruiting
37 participants
Started: Dec 9, 2023 · Completed: Mar 31, 2026
NCT05447546Lead Sponsor
Study to Evaluate HT-6184 in Healthy Subjects
PHASE1Completed
64 participants
Started: Jun 15, 2022 · Completed: Jul 20, 2023
Locations (1)
Headquarters
Lehi, UT, United States
Map
Loading map...